PubMed

Pegaptanib sodium for neovascular age-related macular degeneration: third-year safety results of the VEGF Inhibition Study in Ocular Neovascularisation (VISION) trial.

Singerman LJ, Masonson H, Patel M, Adamis AP, Buggage R, Cunningham E, Goldbaum M, Katz B, Guyer D.

Br J Ophthalmol. 2008 Dec;92(12):1606-11. Epub 2008 Jul 9.PMID: 18614570 [PubMed - indexed for MEDLINE]Related articlesFree article

Pegaptanib sodium for neovascular age-related macular degeneration: two-year safety results of the two prospective, multicenter, controlled clinical trials.

VEGF Inhibition Study in Ocular Neovascularization (V.I.S.I.O.N.) Clinical Trial Group, D'Amico DJ, Masonson HN, Patel M, Adamis AP, Cunningham ET Jr, Guyer DR, Katz B.

Ophthalmology. 2006 Jun;113(6):992-1001.e6. Epub 2006 Apr 27.PMID: 16647134 [PubMed - indexed for MEDLINE]Related articles

Pegaptanib 1-year systemic safety results from a safety-pharmacokinetic trial in patients with neovascular age-related macular degeneration.

Macugen AMD Study Group, Apte RS, Modi M, Masonson H, Patel M, Whitfield L, Adamis AP.

Ophthalmology. 2007 Sep;114(9):1702-12. Epub 2007 May 23.PMID: 17509689 [PubMed - indexed for MEDLINE]Related articles

Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular age-related macular degeneration.

VEGF Inhibition Study in Ocular Neovascularization (V.I.S.I.O.N.) Clinical Trial Group, Chakravarthy U, Adamis AP, Cunningham ET Jr, Goldbaum M, Guyer DR, Katz B, Patel M.

Ophthalmology. 2006 Sep;113(9):1508.e1-25. Epub 2006 Jul 7.PMID: 16828500 [PubMed - indexed for MEDLINE]Related articles

Pegaptanib sodium for the treatment of neovascular age-related macular degeneration: a review.

Kourlas H, Schiller DS.

Clin Ther. 2006 Jan;28(1):36-44. Review.PMID: 16490578 [PubMed - indexed for MEDLINE]Related articles

Pegaptanib for neovascular age-related macular degeneration.

Gragoudas ES, Adamis AP, Cunningham ET Jr, Feinsod M, Guyer DR; VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group.

N Engl J Med. 2004 Dec 30;351(27):2805-16.PMID: 15625332 [PubMed - indexed for MEDLINE]Related articlesFree article

[Clinical experience in the treatment of neovascular age-related macular degeneration with pegaptanib]

Maier M, Feucht N, Huebner M, Lohmann C.

Klin Monbl Augenheilkd. 2008 Jun;225(6):582-7. German. PMID: 18516780 [PubMed - indexed for MEDLINE]Related articles

[Pegaptanib sodium one-year treatment study for neovascular age-related macular degeneration]

Tano Y; Pegaptanib Sodium Multi-center Study Group.

Nippon Ganka Gakkai Zasshi. 2008 Jul;112(7):590-600. Japanese. PMID: 18702350 [PubMed - indexed for MEDLINE]Related articles

Treatment of naïve lesions in neovascular age-related macular degeneration with pegaptanib.

Quiram PA, Hassan TS, Williams GA.

Retina. 2007 Sep;27(7):851-6.PMID: 17891008 [PubMed - indexed for MEDLINE]Related articles

Pegaptanib and ranibizumab for neovascular age-related macular degeneration: a systematic review.

Takeda AL, Colquitt J, Clegg AJ, Jones J.

Br J Ophthalmol. 2007 Sep;91(9):1177-82. Epub 2007 May 2. Review.PMID: 17475698 [PubMed - indexed for MEDLINE]Related articles

Ranibizumab and pegaptanib for the treatment of age-related macular degeneration: a systematic review and economic evaluation.

Colquitt JL, Jones J, Tan SC, Takeda A, Clegg AJ, Price A.

Health Technol Assess. 2008 May;12(16):iii-iv, ix-201. Review.PMID: 18462575 [PubMed - indexed for MEDLINE]Related articlesFree article

Pegaptanib: in exudative age-related macular degeneration.

Siddiqui MA, Keating GM.

Drugs. 2005;65(11):1571-7; discussion 1578-9. Review.PMID: 16033295 [PubMed - indexed for MEDLINE]Related articles

Enhanced efficacy associated with early treatment of neovascular age-related macular degeneration with pegaptanib sodium: an exploratory analysis.

Gonzales CR; VEGF Inhibition Study in Ocular Neovascularization (V.I.S.I.O.N.) Clinical Trial Group.

Retina. 2005 Oct-Nov;25(7):815-27.PMID: 16205558 [PubMed - indexed for MEDLINE]Related articles

Pegaptanib: the first antiangiogenic agent approved for neovascular macular degeneration.

Doggrell SA.

Expert Opin Pharmacother. 2005 Jul;6(8):1421-3. Review.PMID: 16013991 [PubMed - indexed for MEDLINE]Related articles

Anti-VEGF aptamer (pegaptanib) therapy for ocular vascular diseases.

Ng EW, Adamis AP.

Ann N Y Acad Sci. 2006 Oct;1082:151-71. Review.PMID: 17145936 [PubMed - indexed for MEDLINE]Related articles

Pegaptanib for neovascular age-related macular degeneration.

Maberley D.

Issues Emerg Health Technol. 2005 Dec;(76):1-4.PMID: 16544440 [PubMed - indexed for MEDLINE]Related articles

Cost effectiveness of pegaptanib for the treatment of age-related macular degeneration in the UK.

Wolowacz SE, Roskell N, Kelly S, Maciver FM, Brand CS.

Pharmacoeconomics. 2007;25(10):863-79.PMID: 17887807 [PubMed - indexed for MEDLINE]Related articles

Progression of choroidal neovascularization following injection of pegaptanib sodium (macugen) in two eyes with neovascular age-related macular degeneration.

Williams AJ, Fekrat S.

Am J Ophthalmol. 2006 Oct;142(4):683-4.PMID: 17011868 [PubMed - indexed for MEDLINE]Related articles

Safety and efficacy of intravitreal bevacizumab followed by pegaptanib maintenance as a treatment regimen for age-related macular degeneration.

Hughes MS, Sang DN.

Ophthalmic Surg Lasers Imaging. 2006 Nov-Dec;37(6):446-54.PMID: 17152537 [PubMed - indexed for MEDLINE]Related articles

[Treatment of neovascular age-related macular degeneration with intravitreal vascular endothelial growth factor inhibitor--secondary publication]

Larsen M, Sander B, Villumsen JE, Haamann PH, la Cour M, Lund-Andersen H; VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group.

Ugeskr Laeger. 2005 Aug 29;167(35):3301-5. Danish. PMID: 16138974 [PubMed - indexed for MEDLINE]Related articles